{"nctId":"NCT01315249","briefTitle":"QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2011-03"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":523,"armGroups":[{"label":"QVA149","type":"EXPERIMENTAL","interventionNames":["Drug: indacaterol and glycopyrronium (QVA149)","Drug: Placebo to fluticasone/salmeterol"]},{"label":"fluticasone/salmeterol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: fluticasone/salmeterol","Drug: Placebo to indacaterol and glycopyrronium (QVA149)"]}],"interventions":[{"name":"indacaterol and glycopyrronium (QVA149)","otherNames":[]},{"name":"Placebo to fluticasone/salmeterol","otherNames":[]},{"name":"fluticasone/salmeterol","otherNames":[]},{"name":"Placebo to indacaterol and glycopyrronium (QVA149)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Smoking history of at least 10 pack years\n* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease \\[GOLD\\] Guidelines, 2009)\n* Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) \\>40% and \\< 80% of the predicted normal value and post-bronchodilator FEV1/Forced Vital Capacity (FVC) \\<70%\n\nExclusion Criteria:\n\n* Patients who have had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the last year.\n* Patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia.\n* Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1.\n* Patients with concomitant pulmonary disease\n* Patients with a history of asthma\n* Any patient with lung cancer or a history of lung cancer (within last 5 years)\n* Patients with a history of certain cardiovascular co-morbid conditions","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12","description":"Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. FEV1 was normalized by 12 hours (divided by time). This outcome measures absolute values at week 26. Results are obtained from linear mixed model.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":"0.027"},{"groupId":"OG001","value":"1.56","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"Standardized Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12 Hours","description":"Standardized Forced Expiratory Volume in 1 Second (FEV1) was measured with spirometry conducted according to internationally accepted standards. Measurements were made between 0 and 12 hours after treatment. FEV1 was normalized by 12 hours (divided by time). This outcome measures absolute values at week 12. Results are obtained from linear mixed model.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":"0.023"},{"groupId":"OG001","value":"1.59","spread":"0.022"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity at All-time Points (Week 12)","description":"Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. A positive change from baseline in FVC indicates improvement in lung function.\n\nThis outcome measures absolute values at -45 min, -15 min predose; 5 min, 30 min, 1 hr, 2hr, 4 hr, 8 hr, 12 hr post-dose week 12. Results are obtained from linear mixed model.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.37","spread":"0.046"},{"groupId":"OG001","value":"3.16","spread":"0.044"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.37","spread":"0.047"},{"groupId":"OG001","value":"3.17","spread":"0.045"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.44","spread":"0.048"},{"groupId":"OG001","value":"3.20","spread":"0.046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.48","spread":"0.048"},{"groupId":"OG001","value":"3.23","spread":"0.046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.49","spread":"0.049"},{"groupId":"OG001","value":"3.26","spread":"0.047"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.54","spread":"0.048"},{"groupId":"OG001","value":"3.31","spread":"0.046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.49","spread":"0.050"},{"groupId":"OG001","value":"3.33","spread":"0.048"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":"0.048"},{"groupId":"OG001","value":"3.27","spread":"0.046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.45","spread":"0.050"},{"groupId":"OG001","value":"3.26","spread":"0.049"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity at All-time Points (Week 26)","description":"Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. A positive change from baseline in FVC indicates improvement in lung function.\n\nThis outcome measures absolute values at -45 min, -15 min predose; 5 min, 30 min, 1 hr, 2hr, 4 hr, 8 hr, 12 hr post-dose on week 26. Results are obtained from linear mixed model.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.32","spread":"0.047"},{"groupId":"OG001","value":"3.13","spread":"0.045"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":"0.044"},{"groupId":"OG001","value":"3.12","spread":"0.043"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"0.051"},{"groupId":"OG001","value":"3.17","spread":"0.049"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":"0.053"},{"groupId":"OG001","value":"3.23","spread":"0.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.50","spread":"0.051"},{"groupId":"OG001","value":"3.23","spread":"0.049"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.51","spread":"0.051"},{"groupId":"OG001","value":"3.29","spread":"0.049"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.45","spread":"0.053"},{"groupId":"OG001","value":"3.28","spread":"0.050"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":"0.053"},{"groupId":"OG001","value":"3.21","spread":"0.050"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":"0.053"},{"groupId":"OG001","value":"3.18","spread":"0.051"}]}]}]},{"type":"SECONDARY","title":"Focal Score of the Transitional Dyspnea Index (TDI)","description":"Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"0.388"},{"groupId":"OG001","value":"1.45","spread":"0.374"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":"0.388"},{"groupId":"OG001","value":"1.60","spread":"0.376"}]}]}]},{"type":"SECONDARY","title":"Total Score of the St. George's Respiratory Questionnaire (SGRQ-C)","description":"The total score of the St. George's Respiratory Questionnaire (SGRQ-C) is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.74","spread":"1.175"},{"groupId":"OG001","value":"36.03","spread":"1.132"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.45","spread":"1.448"},{"groupId":"OG001","value":"36.68","spread":"1.386"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Daily Number of Puffs of Rescue Medication","description":"Participants maintained a diary to record the daily number of puffs of rescue medication used to treat COPD symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.18","spread":"0.187"},{"groupId":"OG001","value":"-1.90","spread":"0.184"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.32","spread":"0.194"},{"groupId":"OG001","value":"-1.93","spread":"0.191"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Symptom Scores Reported Using the Ediary","description":"Participants maintained an ediary to record daily symptom scores (AM and PM) over 12 weeks and 26 weeks of treatment. This analysis compares the mean symptom scores over 12 weeks and 26 weeks compared to baseline. The diary records morning and evening daily clinical symptoms including cough, wheezing, shortness of breath, sputum volume, sputum purulence, night time awakenings and rescue medication use.\n\nScale ranges: ranges are 0 to 3 with varying scale descriptions that pertain to the question being asked.\n\n0 is the minimum score = \"none\" or \"No symptoms\" or \"never\" or \"No\"\n\n1. = mild, a little\n2. = moderate\n3. = severe For the scale range provided, high values represent a worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"0.135"},{"groupId":"OG001","value":"-1.17","spread":"0.133"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"0.140"},{"groupId":"OG001","value":"-1.24","spread":"0.138"}]}]}]},{"type":"SECONDARY","title":"Inspiratory Capacity (IC) at All-time Points (12 Weeks)","description":"After 12 weeks of treatment, Inspiratory Capacity (IC) was measured via spirometry, conducted according to internationally accepted standards. The mean of 3 acceptable measurements was calculated and reported in liters.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":"0.081"},{"groupId":"OG001","value":"2.31","spread":"0.073"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.55","spread":"0.075"},{"groupId":"OG001","value":"2.42","spread":"0.068"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.54","spread":"0.079"},{"groupId":"OG001","value":"2.43","spread":"0.072"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"0.086"},{"groupId":"OG001","value":"2.45","spread":"0.079"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":"0.080"},{"groupId":"OG001","value":"2.41","spread":"0.073"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"0.079"},{"groupId":"OG001","value":"2.34","spread":"0.070"}]}]}]},{"type":"SECONDARY","title":"Inspiratory Capacity (IC) at All-time Points (26 Weeks)","description":"After 26 weeks of treatment, Inspiratory Capacity (IC) was measured via spirometry, conducted according to internationally accepted standards. The mean of 3 acceptable measurements was calculated and reported in liters.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.25","spread":"0.079"},{"groupId":"OG001","value":"2.22","spread":"0.071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.41","spread":"0.088"},{"groupId":"OG001","value":"2.34","spread":"0.080"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"0.087"},{"groupId":"OG001","value":"2.35","spread":"0.079"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.33","spread":"0.090"},{"groupId":"OG001","value":"2.32","spread":"0.080"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"0.82"},{"groupId":"OG001","value":"2.30","spread":"0.075"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":"0.084"},{"groupId":"OG001","value":"2.27","spread":"0.075"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"The assessment of safety was based on Adverse Events. A summary of adverse events is presented with this outcome, additional details are provided in Adverse Events Section.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":258},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis"]}}}